Tag: annual report

DENVER, June 25, 2026 /PRNewswire/ -- Gates Industrial Corporation plc (NYSE: GTES) (the "Company" or "Gates Industrial Corporation") today announced that its shareholders have...

Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity...

Quarterly Cash Dividend increases 20.0% from $0.20 Per Share to $0.24 Per ShareFORT WORTH, Texas, June 25, 2026 /PRNewswire/ -- AZZ Inc. (NYSE: AZZ),...

ASHBURN, Va., June 25, 2026 /PRNewswire/ - DXC Technology (NYSE: DXC), a leading enterprise technology and innovation partner, today announced that it will release...

COLUMBIA, Mo., June 25, 2026 /PRNewswire/ -- American Outdoor Brands, Inc. (NASDAQ Global Select: AOUT), an innovation company that provides product solutions for outdoor...

Haffner Energy is accelerating the execution of its roadmap with CORE100, H6 and its international developments.

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued...

Updated features help consumers manage collection activity, reduce unwanted collector contact, identify potential rights issues, and explore legal support options through independent attorneys.

Updated features help consumers manage collection activity, reduce unwanted collector contact, identify potential rights issues, and explore legal support options through independent attorneys.

Full Displacement of over 20-year incumbent Approximately 1,000 GPS tracking and house-arrest monitoring units with the opportunity to expandNEW YORK, June 25, 2026 /PRNewswire/...

GENEVA, June 25, 2026 /PRNewswire/ -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company), a global leader in scalable precision neurotherapeutics,...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

RALEIGH, N.C., June 24, 2026 /PRNewswire/ -- Cardinal Infrastructure Group, Inc. (the "Company" or "Cardinal") (Nasdaq: CDNL) today announced the pricing of an upsized...